- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
October 14, 2024Raoul Shah Recognized as New Volunteer Attorney of the Year by Tubman
-
October 14, 2024Robins Kaplan Receives LAAC Award of Merit for Landmark Ruling Benefiting Homeless Veterans
-
October 10, 2024Michael Collyard and Ronald Schutz Named to Minnesota Lawyer’s Power 30: Business Litigation List
-
October 20, 2024License Agreement Disputes:
-
October 21, 2024How Much Did We Invest in AI?
-
October 22, 2024Justice for All: Minnesota's Civil Legal Aid and Pro Bono Landscape
-
September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2017
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Diamox | Teva | Acetazolamide IR Tablets | Heritage Pharmaceuticals | indicated for the treatment of glaucoma, epilepsy, mountain sickness and fluid retention | 1/4/2017 |
Emend | Merck Sharp & Dohme | Aprepitant Capsules | Sandoz | prescribed for patients 12 years of age or older, in combination with other antiemetic agents to help prevent nausea and vomiting caused by certain chemotherapy medicines and for adults to prevent nausea and vomiting after surgery | 1/4/2017 |
MS Contin ER | Purdue Pharma | Morphine Sulfate ER Tablets | Lupin | indicated for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate | 1/13/2017 |
Pacerone | Upsher-Smith Laboratories | Amiodarone Tablets | Mayne Pharma | indicated for life-threatening recurrent ventricular arrhythmia | 1/13/2017 |
Ortho-Cyclen 28 | Janssen | Norgestimate / Ethinyl Estradiol Tablets | Lupin | indicated for use by females of reproductive potential to prevent pregnancy | 1/24/2017 |
Lotronex | Promethius Laboratories | Alosetron Hydrochloride Tablets | Amneal Pharmaceuticals | indicated for women with severe diarrhea-predominant irritable bowel syndrome (IBS) | 1/30/2017 |
Integrilin | Merck | Eptifibatide Injection | Amneal Pharmaceuticals | used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries) | 1/31/2017 |
Imdur | Schering | Isosorbide Mononitrate ER Tablets | Heritage Pharmaceuticals | indicated for the prevention of angina pectoris due to coronary artery disease | 1/31/2017 |
Versed | Hoffman-La Roche | Midazolam Injection | Heritage Pharmaceuticals | used as an agent for preoperative sedation | 1/31/2017 |
Tricor | AbbVie | Fenofibrate Tablets | Camber Pharmaceuticals | reduce cholesterol and triglycerides in the blood | 2/1/2017 |
Bupap | ECR Pharmaceuticals | Butalbital Acetaminophen (APAP) Tablets | Mayne Pharma | indicated for treatment of tension headache (migraine) | 2/16/2017 |
Ritalin LA | Novartis | Methylphenidate ER Capsules | Mayne Pharma | indicated for attention deficit hyperactivity disorder (ADHD) | 2/21/2017 |
Pristiq | Pfizer | Desvenlafaxine Succinate ER Tablets | Breckenridge | indicated for treatment of major depressive disorder (MDD) | 3/1/2017 |
Temovate | Fougera Pharmaceuticals | Clobetasol Propionate Scalp Application | Lupin | indicated for short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | 3/1/2017 |
Pristiq ER | Pfizer | Desvenlafaxine ER Tablets | Teva | indicated for treatment of major depressive disorder (MDD) | 3/1/2017 |
Pristiq | Wyeth | Desvenlafaxine Succinate ER Tablets | Lupin | indicated for the treatment of major depressive disorder (MDD) | 3/2/2017 |
Paxil CR | Apotex | Paroxetine ER Tablets | Lupin | treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder | 3/7/2017 |
Women's Rogaine 5% Minoxidil Foam (OTC) | Johnson & Johnson | Store Brand Equivalent to Women's Rogaine Foam (OTC) | Perrigo | indicated to regrow hair on the top of the scalp | 3/8/2017 |
Hydrocodone Bitartrate / Acetaminophen Tablets | Mikart | Hydrocodone Bitartrate / Acetaminophen Tablets | Lupin | indicated for the relief of moderate to moderately severe pain | 3/9/2017 |
Pristiq | Wyeth | Desvenlafaxine Succinate ER Tablets | Hikma | indicated for the treatment of major depressive disorder (MDD) | 3/10/2017 |
Pristiq | Pfizer | Desvenlafaxine ER Tablets | Mylan | indicated for the treatment of major depressive disorder (MDD) | 3/10/2017 |
Aromasin | Pfizer | Exemestane Tablets | Mylan | indicated in the treatment of certain types of breast cancer in women after menopause | 3/13/2017 |
Minastrin 24 Fe | Allergan | Ferrous Fumarate Tablets | Lupin | indicated for use by females of reproductive age to prevent pregnancy | 3/16/2017 |
Minastrin 24 Fe | Allergan | Norethindrone Acetate / Ethinyl Estradiol / Ferrous Fumarate Tablets | Teva | indicated for use by women to prevent pregnancy | 3/16/2017 |
TOBI | Novartis | Tobramycin Inhalation Solution | Lupin | indicated for the management of cystic fibrosis patients with P. aeruginosa | 3/23/2017 |
Eliphos | Hawthorn Pharmaceuticals | Calcium Acetate IR Tablets | Heritage Pharmaceuticals | indicated to reduce serum phosphorus in patients with end stage renal disease | 3/27/2017 |
Xeloda | Hoffman La Roche | Capecitabine Tablets | ACETO | indicated for the treatment of metastatic breast cancer | 3/28/2017 |
Fusilev | Spectrum Pharmaceuticals | Levoleucovorin for Injection | Amneal Biosciences | is a foliate analog indicated for rescue after high-dose methotrexate therapy for osteosarcoma and diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent over dosage of folic acid antagonists | 3/28/2017 |
Merrem | AstraZeneca | Meropenem Injection | Aurobindo Pharma USA | indicated as single agent therapy for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections such as appendicitis and peritonitis, and bacterial meningitis | 3/28/2017 |
Epzicom | VIIV Healthcare | Abacavir / Lamivudine Tablets | Lupin | indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection | 3/29/2017 |
Epizcom | VIIV Healthcare | Abacavir Sulfate / Lamivudine Tablets | Aurobindo Pharma USA | indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection | 3/30/2017 |
Zyflo CR | Chiesi USA | Zileuton ER Tablets | ACETO | indicated for the chronic treatment of asthma | 3/31/2017 |
GENERICally Speaking Spring 2017
Related Publications
Second Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
June 25, 2024
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
GENERICally Speaking Hatch Waxman Bulletin
June 10, 2024
Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
GENERICally Speaking Hatch Waxman Bulletin
April 30, 2024
Pharmacyclics LLC v. Alvogen Pine Brook LLC
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.